By SPC News Staff
The FDA revoked its emergency use authorization (EUA) for Eli Lilly’s bamlanivimab, which was used as monotherapy for mild to moderate COVID-19 in adults and certain pediatric patients.
Eli Lilly said it asked for the revocation because SARS-CoV-2 viral variants were proving resistant to bamlanivimab monotherapy, resulting in an increased risk for treatment failure. As of mid-March 2021, approximately 20% of viruses sequenced in the United States were reported as